Heterocyclic Building Blocks-piperazine

161357-89-7, 1-(Methylsulfonyl)piperazine hydrochloride is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

4-(5-Chloro-2-methyl-2,3-dihydro-furo[2,3-c]pyridin-2-yl)-piperidine-1-carboxylic acid tert-butyl ester (100 mg) is added to a mixture of 1-(methylsulfonyl)piperazine hydrochloride (70 mg), Pd2(dba)3 (65 mg), Xantphos (123 mg), and potassium tert-butylate (75 mg) in toluene (4 mL) under an argon atmosphere. The reaction mixture is stirred in an oil bath at 105 C. over night. After cooling to room temperature water is added and the mixture is extracted with ethyl acetate. The combined extracts are concentrated in vacuo and the residue is chromatographed on silica gel (cyclohexane/ethyl acetate 50:50?0:100) to give the title compound. LC (method 1): tR=1.03 min; Mass spectrum (ESI+): m/z=481 [M+H]+., 161357-89-7

The synthetic route of 161357-89-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; US2012/322784; (2012); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

59702-07-7, 1-Methylpiperazin-2-one is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

59702-07-7, A mixture of ethyl 3-{[(benzyloxy)carbonyl]amino}-7-bromoquinoline-2-carboxylate (250 mg, 0.58 mmol), 1-methylpiperazin-2-one (130 mg, 1.2 mmol), Pd(OAc)2 (20 mg), dicyclohexyl(2′,6′-diisopropoxybiphenyl-2-yl)phosphine (41 mg, 0.087 mmol), and K3PO4 (490 mg, 2.3 mmol) in tert-butyl alcohol (8 mL) was purged with nitrogen then heated at 100¡ã C. in a sealed vial for 3 h. The mixture was then allowed to cool and EtOAc and water were added. The resulting layers were separated and organic layer was concentrated under reduced pressure. To the resulting bright-yellow solid, 2 mL of dioxane, 2 mL of 2 M NaOH were added. The mixture was heated in 80¡ã C. oil bath with stirring for 0.5 h, then allowed to cooled and neutralized with 4 mL of with 1 M Cl. The red solid formed was collected by filtration and air-dried overnight to give the sub-title compound (24 mg, 9.5percent). LCMS calc. for C26H33N8O2 [M+H]+: m/z=489.3. found: 435.2

The synthetic route of 59702-07-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; INCYTE CORPORATION; Li, Yun-Long; Burns, David M.; Feng, Hao; Xue, Chu-Biao; Wang, Anlai; Pan, Jun; US2014/200216; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

74879-18-8, (S)-(+)-2-Methylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,74879-18-8

(S)+-2-methylpiperazine (10 g) was dissolved in acetonitrile (140 ml) and cooled to 5-10 C. whereupon triethylamine (35 ml) was added, followed by drop wise addition of a solution of trityl chloride (27.9 g) in DCM (80 ml). The reaction was stirred for 1 h at RT. The resulting slurry was cooled to approximately 0 C. then filtered. The filtrate was evaporated in vacuo and the residue was purified by chromatography (silica, 0-1% MeOH/DCM as eluent), then triturated with ether to give the sub-title compound as a white solid yield, 29.8 g.1H NMR CDCl3: delta 7.49-7.37 (6H, m), 7.26 (6H, t), 7.15 (3H, t), 3.38-3.28 (1H, m), 3.22 (1H, dd), 3.11-2.99 (3H, m), 1.74-1.6 (1H, m), 1.44-1.3 (1H, m), 1.11 (3H, d).

The synthetic route of 74879-18-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ASTRAZENECA AB; US2008/255150; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

21655-48-1, cis-2,6-Dimethylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Methyl 4-fluorobenzoate (4.6 g, 29.7 mmol) was dissolved in DMSO (20 mL), followed by the addition of K2CO3 (12.3 g, 89.1 mmol) and 1-ethylpiperazine (7.6 mL, 59.4 mmol). The mixture was heated to 110 ¡ãC and stirred for 10 h before being cooled to room temperature and diluted with water (50 mL) and EtOAc (200 mL). The organic phase was washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography using CH2Cl2?MeOH (10:1) to get 4a (6.4 g, 89.2percent) as a yellow solid.

21655-48-1, The synthetic route of 21655-48-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Cui, Jing; Peng, Xia; Gao, Dingding; Dai, Yang; Ai, Jing; Li, Yingxia; Bioorganic and Medicinal Chemistry Letters; vol. 27; 16; (2017); p. 3782 – 3786;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

304897-49-2, tert-Butyl 4-(4-aminobenzyl)piperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

[0328] A mixture of intermediate 31 (0.10 g, 0.35 mmol), 4-(4-amino-benzyl)-piperazine- 1-carboxylic acid tert-butyl ester (0.12 g, 0.41 mmol), Pd2(dba)3 (30 mg, 0.033 mmol), Xantphos (35 mg, 0.06 mmol) and cesium carbonate (0.23 g, 0.71 mmol) in dioxane/DMF (3/1, 4 mL) was sealed in a microwave reaction tube and irradiated with microwave at 160 0C for 20 min. After cooling to room temperature, the cap was removed and the resulting mixture filtered. The filtered solid was washed with DCM and the filtrate concentrated. The residue was purified by flash chromatography on silica gel (hexanes to 60% EtOAc/hexanes) to afford the Boc-protected precursor. To a solution of the precursor in DCM (5 mL) was added TFA (3 mL). The mixture was stirred at room temperature for 1 h, concentrated and the residue purified by HPLC. The corrected fractions were combined and poured into saturated NaHCO3 solution (30 mL). The combined aqueous layers were extracted with EtOAc (2 x 30 mL) and the combined organic layers washed with brine, dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated and then taken up in minimum amount of EtOAc. Hexanes were added until solid precipitated. After filtration, the title compound was obtained as a white solid (13 mg, 9%).[0329] 1H NMR (500 MHz, DMSO-d6): delta 2.11 (s, 3H), 2.30-2.40 (m, 4H), 2.83 (t, J= 4.8 Hz5 4H), 3.37 (s, 2H), 3.75 (s, 3H), 7.08 (d, J= 8.6 Hz, 2H), 7.29 (d, J= 8.6 Hz, IH), 7.43 (dd, J= 8.6, 2.2 Hz, IH), 7.47 (d, J= 2.2 Hz, IH), 7.59 (d, J= 8.6 Hz, 2H), 7.91 (s, IH), 8.37 (s, IH), 8.99 (s, IH). MS (ES+): m/z 439 (M+H)+.

304897-49-2, As the paragraph descriping shows that 304897-49-2 is playing an increasingly important role.

Reference£º
Patent; TARGEGEN, INC.; WO2007/53452; (2007); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

70261-82-4,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.70261-82-4,4-(4-Methylpiperazin-1-ylmethyl)phenylamine,as a common compound, the synthetic route is as follows.

4-Amino-N-[4-[(4-methylpiperazin-1-yl) methyl] phenyl]-1Hpyrazole-3-carboxamide (5): The mixture of N-methylpiperazine (4.9 mL, 44.2 mmol) and triethylamine (12 mL,86.3 mmol) in dichloromethane (20 mL) was added dropwiseto a stirred solution of Nitro-benzyl bromide 1 (10.0 mg,46.3 mmol) in dichloromethane (100 mL) under the ice-waterbath and was refluxed for 1 h. The reaction mixture was extractedwith chloroform (100 mL¡Á3), washed with water andsaturated sodium chloride each time (100 mL¡Á1). The organicphase was dried with anhydrous magnesium sulfate, filtered,evaporated under vacuum to give pale yellow solid 2. Withoutfurther purification, 2 mixed with FeO(OH)/C (catalyst 2.0 g)and 95% ethanol (100 mL) were kept refluxing and dropwiseadded the mixture of hydrazine hydrate (25 mL) and 95%ethanol (20 mL), then filtrated when the solution was hot. Theresidue was washed with hot ethanol (30 mL¡Á2). The solventwas distilled under vacuum to give white solid 3 (6.7 g), thenmixed with 4-nitro-1H-pyrazole-3-acid (6.3 g, 40.0 mmol),EDCI (8.4 g, 43.8 mmol) and HOBT (6.0 g, 44.4 mmol) in anhydrousDMF (100 mL), stirred for 24 h at room temperature.The reaction mixture was poured into ice water (200 mL).A large amount of yellow solid precipitation was acquired.The pure product 4 was got from recrystallizing with mixedsolvent of methanol and ethyl acetate, then the same processof hydrazine hydrate reduction was done with the catalyst ofFeO(OH)/C. The solvent was distilled under vacuum to give white solid 5 (3.5 g). Yield= 63.9%; mp 199-201C; IR (KBr)cm-1: 3369, 3227 (NH2), 1346 (C= C), 1456 (C= N) pyrazole,646 (ArH); 1H-NMR (300 MHz, DMSO-d6) delta (ppm): 2.1 (3H,s, -CH3), 2.3-2.5 (8H, m, -CH2-), 3.3 (2H, s, -CH2-), 4.7(1H, s, -NH2), 7.1-7.2 (3H, m, ArH), 7.7 (2H, d, J=10.5 Hz,ArH), 9.7 (1H, s, -NHCO-), 12.7 (1H, s, Pyrazole); MS m/z:315.82 (M+); Anal. Calcd for C16H22N6O: C, 61.13; H, 7.05; N,26.73; O, 5.09. Found: C, 61.31; H, 6.84; N, 26.52.

The synthetic route of 70261-82-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Lu, Yi; Ran, Ting; Lin, Guowu; Jin, Qiaomei; Jin, Jianling; Li, Hongmei; Guo, Hao; Lu, Tao; Wang, Yue; Chemical and Pharmaceutical Bulletin; vol. 62; 3; (2014); p. 238 – 246;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.120737-78-2,tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

A solution of tert-butyl 2-methylpiperazine-1-carboxylate (1.5 g, 7.49 mmol, 1 equiv), 2-chloro-5-(trifluoromethyl)pyrimidine (1.37 g, 7.50 mmol, 1.00 equiv), and K2CO3 (2.07 g, 15.0 mmol, 2.00 equiv) in NMP (20 mL) was stirred for 16 h at 85 C. The reaction mixture was cooled to RT, followed by addition of water. The resulting solids were precipitated and collected by filtration, and then washed with water and drying under vacuum to afford 2.5 g of title compound as a light yellow solid. LCMS. [M+H]+ 347., 120737-78-2

120737-78-2 tert-Butyl 2-methylpiperazine-1-carboxylate 15087784, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; Ribon Therapeutics Inc.; Vasbinder, Melissa Marie; Schenkel, Laurie B.; Swinger, Kerren Kalai; Kuntz, Kevin Wayne; (410 pag.)US2019/330194; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13754-38-6,1-Benzoylpiperazine,as a common compound, the synthetic route is as follows.

Synthesis of (4-(2-amino-9-(3-(4-ethylpiperazin-l-yl)propyl)-9H-purin-6-yl)piperazin-l- yl)(phenyl)methanone (18): Compound 17 was dissolved in acetonitrile (5 mL), potassium carbonate (1.2 g, 0.03 mmol) and phenyl(piperazine-l -yl) methanone (0.84 g, 0.03 mmol) were added. The reaction was stirred for 2 hours under N2 atmosphere condition at 100 C. Acetonitrile was evaporated under the vacuum, then water was added to the reaction mixture to get precipitate which was filter off to get precipitate (0.8 g, yield 70%) of product 18. 1H NMR (300 MHz, CDCI3) delta ppm 7.49 (s, 1H), 7.42 (d, J = 9 Hz, 4H), 4.63 (s, 2H), 4.26 (s, 3H), 4.09 (t, J = 6 Hz, 2H), 3.89 (s, 2H), 3.54 (s, 2H), 2.42 (d, J = 6 Hz, 8H), 2.28-2.40 (m, 3H), 1.85-2.03 (m, 3H), 1.08 (t, J = 6 Hz, 3H). ESI-MS m/z 478.34 (M+H)., 13754-38-6

13754-38-6 1-Benzoylpiperazine 762654, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH; TALUKDAR, Arindam; GANGULY, Dipyaman; MUKHERJEE, Ayan; PAUL, Barnali; RAHAMAN, Oindrila; KUNDU, Biswajit; ROY, Swarnali; DEBLINA, Raychaudhuri; (60 pag.)WO2019/92739; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.196811-66-2,tert-Butyl 4-carbamothioylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

To a stirred solution of terf-butyl 4-carbamothioylpiperazine-1-carboxylate (synthesized according to Example 5, Step 1, 1.3 g, 5.3 mmol) in dioxane (10 mL,), TEA (1 mL,, 7 mmol) and 1-bromo-3,3- dimethylbutan-2-one (0.94 mL,, 6.8 mmol) were added at rt and stirred for 16 h at 90 C. The completion of the reaction was monitored by TLC. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, concentrated under vacuum and the resulting crude product was taken as such for next step without further purification. Yield: 88% (1.5 g, black liquid). LCMS: (Method A) 326.2 (M+H), Rt. 3.75 min, 60.4% (Max)., 196811-66-2

The synthetic route of 196811-66-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ASCENEURON SA; QUATTROPANI, Anna; KULKARNI, Santosh S.; GIRI, Awadut Gajendra; (243 pag.)WO2016/30443; (2016); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.31166-44-6,1-Cbz-Piperazine,as a common compound, the synthetic route is as follows.

Benzyl 1-piperazinecarboxylate (1.268 mL, 6.575 mmol) and tert-Butyl 2,4-dichloro-5,6-dihydropyrido[3 4-d]pyrimidine-7(8H)- carboxylate (2 g, 6.575 mmol) were dissolved in dimethyl acetamide (10 mL) and treated with N-ethyl-N-isopropylpropan-2-amine (3.445 mL, 19.73 mmol). The reaction mixture was stirred at 85 C for 2 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, washed with water and brine, dried over MgS04, filtered and concentrated. The concentrate was purified by chromatography (CombiFlash, 0%-50% ethyl acetate:Hexanes as the eluent to provide the product (2.69g, 83%). ES+APCI MS m/z 488.2, 490.2 [M+H]+ .

31166-44-6, The synthetic route of 31166-44-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MIRATI THERAPEUTICS, INC.; ARRAY BIOPHARMA, INC.; FISCHER, John, P.; FELL, Jay, Bradford; BLAKE, James, F.; HINKLIN, Ronald, Jay; MEJIA, Macedonio, J.; HICKEN, Erik, James; CHICARELLI, Mark, Joseph; GAUDINO, John, J.; VIGERS, Guy, P.A.; BURGESS, Laurence, E.; MARX, Matthew, Arnold; CHRISTENSEN, James, Gail; LEE, Matthew, Randolf; SAVECHENKOV, Pavel; ZECCA, Henry, J.; (529 pag.)WO2017/201161; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics